Today: 2 February 2026
Subscribe
Browse Category

NASDAQ:ATOS News 2 February 2026

Atossa Therapeutics (ATOS) enters reverse-split Monday as Nasdaq compliance clock tightens

Atossa Therapeutics (ATOS) enters reverse-split Monday as Nasdaq compliance clock tightens

New York, Feb 2, 2026, 05:06 (EST) — Premarket Atossa Therapeutics, Inc. is set to implement a one-for-fifteen reverse stock split on Monday, according to a Nasdaq notice. Following the split, the shares will trade under a new CUSIP in the U.S. securities system. (NASDAQ Trader) Why it matters now: the company is targeting a boost in its per-share price,…
2 February 2026
····

Stock Market Today

  • Klaviyo (KVYO) Share Price Drops 52% Amid Mixed Valuation Signals
    February 2, 2026, 8:08 AM EST. Klaviyo's shares have plummeted 52.4% over the past year, closing recently at $22.21. The marketing automation company's fall has sparked debate on whether the stock now offers a bargain or remains overpriced. A Discounted Cash Flow (DCF) analysis values Klaviyo at $11.70 per share, suggesting an 89.8% overvaluation relative to the current price. Despite free cash flow projections increasing through 2035, the DCF model's conservative estimates weigh heavily. Klaviyo trades at a price-to-sales (P/S) ratio of 5.81, reflecting investor expectations for growth amid concerns about execution risks. The stock's mixed valuation signals fuel ongoing uncertainty about its long-term prospects within the software sector.
Go toTop